The launched of vildagliptin (Glavus®) has been delayed by a safety update on liver enzyme elevations according to PharmaTimes.
The article states that liver enzyme elevations were less frequent in patients taking 50mg each day or 50mg twice daily compared to those taking 100mg daily. This finding has raised safety concerns and may impact on the use of this drug as a true once-daily medication.
Action: The gliptins are new agents and their place in therapy is where other agents have failed or are not tolerated. Previous recommendations are unchanged.
|« Rosuvastatin disappoints in HF||Lumiracoxib licence suspended »|